胖厚性心肌病的非药物治疗近况(国外英文资料).docVIP

肥厚性心肌病的非药物治疗现状 【 abstract 】 the treatment of hypertrophic cardiomyopathy is a review of the present situation of non-drug treatment of hypertrophic cardiomyopathy. [keywords] cardiomyopathy, hypertrophy; Treatment; Program evaluation Hypertrophic cardiomyopathy (HCM) is the asymmetry of myocardial hypertrophy, left ventricular diastolic filling is limited and the decrease of the ventricular wall compliance as the basic characteristics of a kind of hereditary disease, hypertrophic interventricular septum, and the left ventricular contraction anterior mitral valve to the interval displacement, causing left ventricular outflow tract (1 eft ventricular outflow tract, LVOT) stenosis and obstruction and mitral valve regurgitation, clinical manifestations of exertional dyspnea, angina pectoris, syncope and sudden death, some patients have no symptoms. The incidence of HCM is about one in 500, the most common cause of sudden death among teenagers. Because of the poor quality of life, sudden death rate, how to improve symptoms actively and effectively, preventing sudden death is a constant concern. Drug treatment is preferred, but it still does not work for a significant number of patients, requiring further intervention or surgical intervention. 1 double-cavity pacemaker (DDD) Mechanism of 1.1 In the mid-1970s, DDD was used to treat HCM. After placing DDD, ventricular excited from ministry of right ventricular apex, exciting interventricular septum in advance before the ventricular systolic ejection, contraction in advance and remove the outflow, reduce mitral valve systolic forward, so as to reduce LVOT obstruction. The appropriate room interventricular phase can guarantee the capture of the pacemaker against ventricle, and the order of the room in order to contract. Topilski etc. [2] on postoperative patients with long-term follow-up, DDD using echocardiography evaluation found that 75% of patients need to be repeated adjustment of atrioventricular interphase to maximize